Trial Profile
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Mipsagargin (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GenSpera
- 26 Apr 2016 Results published in the British Journal of Cancer
- 08 Sep 2014 According to a GenSpera media release, interim data from this and other Phase II trial (see profile 224742) presented at the 8th International Liver Cancer Association (ILCA) Conference
- 05 Nov 2013 Status changed from active, no longer recruiting to completed based on final results presented at EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics, according to a GenSpera media release.